P139 (0169) BRENTUXIMAB VEDOTIN ALONE AND IN COMBINATION WITH BENDAMUSTINE AS SALVAGE THERAPY FOR PRIMARY REFRACTORY OR RELAPSED HODGKIN LYMPHOMA: MULTICENTRE EXPERIENCE OF THE POLISH LYMPHOMA RESEARCH GROUP

P139 (0169) BRENTUXIMAB VEDOTIN ALONE AND IN COMBINATION WITH BENDAMUSTINE AS SALVAGE THERAPY FOR PRIMARY REFRACTORY OR RELAPSED HODGKIN LYMPHOMA: MULTICENTRE EXPERIENCE OF THE POLISH LYMPHOMA RESEARCH GROUP

Bibliographic Details
Format:	Article
Language:	English
Published:	Wiley 2018-10-01
Series:	HemaSphere
Online Access:	http://journals.lww.com/10.1097/01.HS9.0000547982.14522.a6

Similar Items

Brentuximab vedotin for relapsed or refractory Hodgkin’s lymphoma
by: Chen R, et al.
Published: (2015-03-01)

Brentuximab vedotin as a salvage treatment for relapsed and refractory Hodgkin lymphoma patients in Taiwan
by: Feng-Ming Tien, et al.
Published: (2019-10-01)

P135 (0160) BRENTUXIMAB-VEDOTIN + BENDAMUSTINE: A HIGHLY EFFECTIVE SALVAGE TREATMENT UN REFRACTORY/RELAPSED PATIENTS WITH HODGKIN LYMPHOMA
Published: (2018-10-01)

Brentuximab vedotin in the treatment of relapsed and refractory forms of Hodgkin lymphoma
by: E A Demina
Published: (2016-06-01)

Role of brentuximab vedotin in the treatment of relapsed or refractory Hodgkin lymphoma
by: Siddiqi T, et al.
Published: (2014-02-01)

TARGETED THERAPY WITH BRENTUXIMAB VEDOTIN IN RELAPSED AND REFRACTORY FORMS OF CLASSICAL HODGKIN LYMPHOMA
by: E. A. Demina
Published: (2017-11-01)

COST-EFFECTIVENESS ANALYSIS OF BRENTUXIMAB VEDOTIN IN ADULTS WITH RELAPSED OR REFRACTORY HODGKIN’S LYMPHOMA
by: G. R. Khachatryan, et al.
Published: (2016-04-01)

Brentuximab vedotin in pediatric Hodgkin lymphoma
by: Shuvadeep Ganguly, et al.
Published: (2022-01-01)

P111: Phase I Trial of Brentuximab Vedotin plus Cyclosporine in Relapsed/Refractory Hodgkin Lymphoma
by: Swetha Kambhampati, et al.
Published: (2022-10-01)

P112: Phase II Trial of Brentuximab Vedotin plus ibrutinib in Relapsed/Refractory Hodgkin Lymphoma
by: Matthew Mei, et al.
Published: (2022-10-01)

Nivolumab plus Brentuximab vedotin +/- bendamustine combination therapy: a safe and effective treatment in pediatric recurrent and refractory classical Hodgkin lymphoma
by: Patrick Greve, et al.
Published: (2023-07-01)

Overall survival with brentuximab vedotin in advanced Hodgkin lymphoma
by: Shuvadeep Ganguly, et al.
Published: (2022-01-01)

Brentuximab Vedotin and Pembrolizumab Combination in Patients with Relapsed/Refractory Hodgkin Lymphoma: A Single-Centre Retrospective Analysis
by: Fulvio Massaro, et al.
Published: (2022-02-01)

Pharmacoeconomic analysis of therapy with brentuximab vedotin, nivolumab and pembrolizumab in patients with relapsed Hodgkin’s lymphoma
by: N. A. Avxentyev, et al.
Published: (2020-12-01)

Brentuximab vedotin is the first target drug in the treatment of hodgkin lymphoma
by: G. S. Tumyan
Published: (2018-11-01)

P017 (0120) IMMUNOLOGIC BIOMARKERS OF RESPONSE AND RESISTANCE TO BRENTUXIMAB VEDOTIN IN PATIENTS WITH RELAPSED OR REFRACTORY CLASSICAL HODGKIN LYMPHOMA
Published: (2018-10-01)

Results of a multicentre UK-wide retrospective study evaluating the efficacy of brentuximab vedotin in relapsed, refractory classical Hodgkin lymphoma in the transplant naive setting
by: Eyre, T, et al.
Published: (2017)

Hodgkin Lymphoma on Hemodialysis Successfully Treated with Extended Courses of Brentuximab Vedotin
by: Ayana Uchimura, et al.
Published: (2022-03-01)

The role of radiotherapy in patients with refractory Hodgkin's lymphoma after treatment with brentuximab vedotin and/or immune checkpoint inhibitors
by: Ruizhi Zhao, et al.
Published: (2024-03-01)

P104: Consolidation Therapy with Brentuximab Vedotin after Autologous Stem Cell Transplantation for Relapsed/Refractory Hodgkin Lymphoma in the Czech Republic.
by: Jozef Michalka, et al.
Published: (2022-10-01)

Potentials of brentuximab vedotin in the treatment of relapse/refractory cutaneous T-cell lymphomas: literature review and authors’ observation
by: L. G. Gorenkova, et al.
Published: (2019-07-01)

Treatment patterns and costs of care for patients with relapsed and refractory Hodgkin lymphoma treated with brentuximab vedotin in the United States: A retrospective cohort study.
by: Shelagh M Szabo, et al.
Published: (2017-01-01)

Successful salvage therapy for refractory primary cutaneous gamma-delta T-cell lymphoma with a combination of brentuximab vedotin and gemcitabine
by: Sophie Voruz, et al.
Published: (2021-05-01)

Brentuximab vedotin resistance in classic Hodgkin's lymphoma and its therapeutic strategies: a review
by: Dayeeta Bera, et al.
Published: (2024-02-01)

Hodgkin’s Lymphoma after Autologous Stem-Cell Transplantation: Effective Consolidation with Brentuximab Vedotin
by: Adrian Schmidt
Published: (2020-11-01)

Safe prolonged use of brentuximab vedotin in a patient with Classical Hodgkin Lymphoma on hemodialysis
by: Aimee Schad, et al.
Published: (2023-09-01)

Cost-effectiveness of brentuximab vedotin in advanced stage Hodgkin’s lymphoma: a probabilistic analysis
by: A. J. N. Raymakers, et al.
Published: (2020-10-01)

P110 (0014) SUCCESSFUL TREATMENT OF HODGKIN LYMPHOMA WITH BRENTUXIMAB VEDOTIN RELAPSING AFTER AUTOLOGOUS STEM CELL TRANSPLANTATION
Published: (2018-10-01)

Successful brentuximab vedotin monotherapy against late relapse of classical Hodgkin lymphoma 6 years after first remission
by: Kana Nagashima, et al.
Published: (2020-03-01)

Brentuximab vedotin in children and adolescents with Hodgkin’s lymphoma and anaplastic large cell lymphoma – literature review and own experience
by: N. V. Myakova, et al.
Published: (2016-03-01)

Real experience of brentuximab vedotin for cutaneous T cell lymphomas
by: F. Keklik Karadag, et al.
Published: (2020-10-01)

Assessment of the efficiency of Brentuximab Vedotin in patients with pulmonary Hodgkin Lymphoma by the mean of neutrophil to lymphocyte ratio
by: Gokhan Erdem, et al.
Published: (2018-04-01)

Remission of relapsed/refractory classical Hodgkin lymphoma induced by brentuximab vedotin and pembrolizumab combination after allogeneic hematopoietic stem cell transplantation: a case report
by: Federica Giannotti, et al.
Published: (2024-03-01)

T098: Brentuximab Vedotin plus ESHAP (BRESHAP) versus ESHAP in Patients with Relapsed or Refractory Classical Hodgkin’s Lymphoma. Interim Results of the BRESELIBET Prospective Clinical Trial.
by: Anna Sureda-Balari, et al.
Published: (2022-10-01)

P109: One-Day Brentuximab-Bendamustine (120mg/m2) every 21 days is a feasible and safe treatment for relapsed/refractory Hodgkin lymphoma
by: Hannah Moatti, et al.
Published: (2022-10-01)

Brentuximab vedotin for treatment of relapsed or refractory malignant lymphoma: results of a systematic review and meta-analysis of prospective studies
by: Chen R, et al.
Published: (2015-04-01)

Brentuximab vedotin use in pediatric anaplastic large cell lymphoma
by: Jennifer E. Agrusa, et al.
Published: (2023-05-01)

Safety of Concurrent Radiation Therapy With Brentuximab Vedotin in the Treatment of Lymphoma
by: Susan Y. Wu, MD, et al.
Published: (2023-11-01)

The Role of Brentuximab Vedotin (BV) as Second-Line Treatment of Refractory Classical Hodgkin Lymphoma (cHL) in the Era of Pandemic COVID-19
by: Rajabto W, et al.
Published: (2022-06-01)

Relapsed/Refractory Hodgkin Lymphoma
by: Semira Sheikh, et al.
Published: (2018-06-01)